Dr. Philip E. Lammers
Claim this profileBaptist Memorial Hospital and Cancer Center-Memphis
Studies Breast Cancer
Studies Non-Small Cell Lung Cancer
20 reported clinical trials
35 drugs studied
About Philip E. Lammers
Education:
- Completed undergraduate studies at the University of Notre Dame, Notre Dame, IN.
- Graduated from Indiana University School of Medicine, Indianapolis, IN, in 2006.
- Residency in Internal Medicine at Barnes-Jewish Hospital, Washington University Medical Center, St. Louis, MO (2006-2009).
- Fellowship in Hematology and Medical Oncology at Vanderbilt University Medical Center, Nashville, TN (2010-2013).
Experience:
- Board-certified in Internal Medicine, Hematology, and Medical Oncology.
- Serves as Medical Director of Clinical Oncology Research and leads the Clinical Trials Committee at Baptist Cancer Center.
- Active in Baptist's Mid-South Minority and Underserved NCORP and leads the Multidisciplinary Breast Cancer Clinic.
- Has secured national grant funding and is a member of the SWOG Breast Cancer Committee.
- Affiliated with Baptist Memorial Hospital-Tipton and Baptist Memorial Hospital-Memphis.
Area of expertise
1Breast Cancer
Stage IV
ER negative
PR negative
2Non-Small Cell Lung Cancer
Stage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Philip E. Lammers is currently running
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
More about Philip E. Lammers
Clinical Trial Related4 years of experience running clinical trials · Led 20 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Philip E. Lammers has experience with
- Carboplatin
- Paclitaxel
- Pembrolizumab
- Atezolizumab
- Pemetrexed
- Bevacizumab
Breakdown of trials Philip E. Lammers has run
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Philip E. Lammers specialize in?
Philip E. Lammers focuses on Breast Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are ER negative.
Is Philip E. Lammers currently recruiting for clinical trials?
Yes, Philip E. Lammers is currently recruiting for 8 clinical trials in Memphis Tennessee. If you're interested in participating, you should apply.
Are there any treatments that Philip E. Lammers has studied deeply?
Yes, Philip E. Lammers has studied treatments such as Carboplatin, Paclitaxel, Pembrolizumab.
What is the best way to schedule an appointment with Philip E. Lammers?
Apply for one of the trials that Philip E. Lammers is conducting.
What is the office address of Philip E. Lammers?
The office of Philip E. Lammers is located at: Baptist Memorial Hospital and Cancer Center-Memphis, Memphis, Tennessee 38120 United States. This is the address for their practice at the Baptist Memorial Hospital and Cancer Center-Memphis.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.